|Bid||18.2700 x 500|
|Ask||0.0000 x 0|
|Day's Range||22.8538 - 22.8538|
|52 Week Range||20.2000 - 24.6500|
|PE Ratio (TTM)||268.87|
|Expense Ratio (net)||0.30%|
Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.
Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company that specializes in researching, developing, manufacturing, and marketing a broad range of healthcare products.
Sanofi (SNY) is consistently investing in and focusing on its R&D (research and development) strategy. The company has a number of key technology platforms driving its multitargeting strategy in R&D. Sanofi spends ~15% of its total sales on R&D. In recent years, Sanofi has transformed its R&D approach and has shifted toward biologics and combination therapies.
On October 20, 2017, the U.S. Food and Drug Administration (or FDA) approved GlaxoSmithKline’s (GSK) Zoster vaccine recombinant and adjuvanted vaccine, Shingrix, as a preventive measure against herpes zoster infection of shingles for adults over 50 years. This approval was based on solid efficacy, safety, and immunogenicity demonstrated by this non-live, recombinant subunit vaccine phase three program consisting of around 38,000 people.
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.
In 1H17, Teva Pharmaceutical's (TEVA) respiratory franchise reported revenues of ~$626 million, or ~8% lower YoY (year-over-year).
GlaxoSmithKline's (GSK) vaccine business includes meningitis vaccines, influenza vaccines, and the established vaccines in its portfolio.
Novartis is focused on integrated drug development as well as centralized operations, and its new organizational structure has proven to be beneficial.
Sanofi’s (SNY) established products contributed over 29.5% of its total revenue in 2Q17. Established product revenue, which fell 2.3% at constant exchange rates in 2Q17, stood at 2.6 billion euros. Lower…...
Analysts expect Novartis's 2Q17 revenues for Alcon to increase operationally following strong sales of products from the vision care franchise.